非何傑金氏淋巴瘤治療市場規模、佔有率和成長分析（按治療類型、藥物類別、給藥途徑、適應症和地區分類）－2026-2033年產業預測

預計到 2024 年，全球非何傑金氏淋巴瘤治療市場規模將達到 55.6 億美元，到 2025 年將達到 59.4 億美元，到 2033 年將達到 101.3 億美元，預測期（2026-2033 年）的複合年成長率為 6.9%。

全球非何傑金氏淋巴瘤(NHL) 治療市場的主要驅動力是人口老化導致 NHL 發病率上升，以及早期檢測技術進步帶來的新發現。隨著確診患者數量的增加，對創新有效治療方法的需求日益成長，促使醫療機構和製藥公司致力於研發新的治療方法。為了滿足這項需求，研發投入不斷增加。此外，免疫療法，特別是嵌合體抗原受體 (CAR) T 細胞療法的進步，透過有效靶向並摧毀癌細胞，正在革新治療方案，從而改善患者的預後。這一趨勢鼓勵人們進一步探索個人化治療方案，從而顯著推動 NHL 治療市場的成長。

推動全球非何傑金氏淋巴瘤藥物市場發展的因素

由於人口老化和生活方式等因素，非何傑金氏淋巴瘤的發生率不斷上升，顯著推動了全球該疾病治療藥物市場的發展。隨著診斷病例的增加，對免疫療法、化療和標靶治療等先進治療方案的需求也日益成長。這一趨勢推動了市場持續創新和投資，促進了有效治療方案的開發和廣泛應用。隨著對個人化醫療的日益重視，治療策略格局不斷演變，既滿足了對更有效治療性介入的迫切需求，也為市場擴張創造了更多機會。

限制全球非何傑金氏淋巴瘤藥物市場的因素

全球非何傑金氏淋巴瘤治療市場面臨許多挑戰，主要原因是人們對該疾病的認知度較低，以及許多發展中地區早期診斷困難。醫療基礎設施和診斷設施的匱乏，使得患者難以及時發現病情並獲得治療。這最終影響了對非何傑金氏淋巴瘤治療藥物的需求，並阻礙了市場的整體成長。如果沒有有效的教育計畫和更完善的醫療資源，該市場的發展可能會受到限制，因為患者無法及時獲得必要的治療，這將進一步加劇這些地區醫療服務提供者面臨的挑戰。

非何傑金氏淋巴瘤治療市場的全球趨勢

全球非何傑金氏淋巴瘤(NHL) 治療市場正經歷顯著成長，這主要得益於創新免疫療法，尤其是 CAR-T 細胞療法的興起。這些先進治療方法利用人體自身的免疫反應，特異性靶向並清除淋巴瘤細胞，為傳統治療方法不佳的複發或難治性患者帶來了新的希望。因此，為提高治療效果和改善患者預後，免疫療法藥物的研發投入正在增加。這種向個人化醫療的轉變鞏固了免疫療法在 NHL 治療中的地位，並推動了市場擴張。這也反映了腫瘤學領域標靶治療策略的更廣泛趨勢。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球非何傑金氏淋巴瘤藥物市場規模（按治療方法類型和複合年成長率分類）（2026-2033 年）

• 化療
• 免疫療法
• 標靶治療
• 放射線治療

全球非何傑金氏淋巴瘤藥物市場規模（依藥物類別分類）及複合年成長率（2026-2033 年）

• 單株抗體
• 化療藥物
• 布魯頓蛋白酪氨酸激酶抑制劑
• 免疫調節劑

全球非何傑金氏淋巴瘤藥物市場規模（按給藥途徑和複合年成長率分類）（2026-2033 年）

• 靜脈注射
• 口服
• 皮下注射

全球非何傑金氏淋巴瘤藥物市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 瀰漫性大B細胞淋巴瘤
• 濾泡性淋巴瘤
• 套細胞淋巴瘤
• 伯基特淋巴瘤

全球非何傑金氏淋巴瘤藥物市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Roche（Switzerland）
• Novartis（Switzerland）
• Gilead Sciences（USA）
• Bristol-Myers Squibb（USA）
• AbbVie（USA）
• Merck & Co.（USA）
• AstraZeneca（United Kingdom）
• Sanofi（France）
• Bayer AG（Germany）
• Johnson & Johnson（USA）
• Pfizer（USA）
• Eli Lilly and Company（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Genmab（Denmark）
• Seagen Inc.（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Kyowa Kirin Co., Ltd.（Japan）
• Spectrum Pharmaceuticals Inc.（USA）
• Autolus Therapeutics（UK）
• Immuneel Therapeutics Private Limited（India）

結論與建議

Global Non-Hodgkin Lymphoma Therapeutics Market size was valued at USD 5.56 Billion in 2024 and is poised to grow from USD 5.94 Billion in 2025 to USD 10.13 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The global Non-Hodgkin Lymphoma (NHL) therapeutics market is primarily influenced by the rising incidence of NHL, linked to an aging population and advancements in diagnostic methods that facilitate earlier detection. As more patients are diagnosed, the demand for innovative and effective treatments grows, prompting healthcare providers and pharmaceutical companies to focus on new therapeutic developments. Investment in research and development initiatives is increasing to address this demand. Additionally, advancements in immunotherapy, particularly Chimeric Antigen Receptor (CAR) T-cell therapies, are revolutionizing treatment options by effectively targeting and destroying cancer cells, leading to improved patient outcomes. This trend encourages further exploration of personalized treatment approaches, thereby stimulating significant growth within the NHL therapeutics landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Non-Hodgkin Lymphoma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Non-Hodgkin Lymphoma Therapeutics Market Segments Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market is segmented by Therapeutic Type, Drug class, Administration Route, Indication and region. Based on Therapeutic Type, the market is segmented into Chemotherapy, Immunotherapy, Targeted Therapy and Radiation Therapy. Based on Drug class, the market is segmented into Monoclonal Antibodies, Chemotherapeutic Agents, Bruton's Tyrosine Kinase Inhibitors and Immunomodulators. Based on Administration Route, the market is segmented into Intravenous, Oral and Subcutaneous. Based on Indication, the market is segmented into Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma and Burkitt Lymphoma. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Non-Hodgkin Lymphoma Therapeutics Market

The rising prevalence of non-Hodgkin lymphoma, influenced by factors such as aging demographics and lifestyle choices, significantly propels the global therapeutics market for this condition. An increasing number of diagnoses leads to heightened demand for advanced treatment solutions, including immunotherapies, chemotherapy, and targeted therapies. This dynamic encourages ongoing innovation and investment within the market, thereby enhancing the development and availability of effective options for patients. As the focus on personalized medicine grows, the landscape of treatment strategies evolves, creating further opportunities for market expansion in response to the critical need for improved therapeutic interventions.

Restraints in the Global Non-Hodgkin Lymphoma Therapeutics Market

The Global Non-Hodgkin Lymphoma Therapeutics market faces notable obstacles due to limited awareness of the disease in various developing regions and challenges related to early diagnosis. Insufficient healthcare infrastructure and a lack of diagnostic facilities complicate timely detection and treatment options for patients. This ultimately impacts the demand for non-Hodgkin lymphoma therapeutics and hampers the overall growth of the market. Without effective educational programs and improvements in healthcare resources, the progression of this market may remain constrained as patients are unable to access necessary therapies in a timely manner, further exacerbating the challenges faced by healthcare providers in these regions.

Market Trends of the Global Non-Hodgkin Lymphoma Therapeutics Market

The global Non-Hodgkin Lymphoma (NHL) therapeutics market is experiencing significant growth driven by the rise of innovative immunotherapy approaches, particularly CAR-T cell therapy. These advanced treatments leverage the body's immune responses to specifically target and eliminate lymphoma cells, offering hope for patients with relapsed or refractory cases where traditional therapies fall short. As a result, there is an increasing investment in research and development of immunotherapeutic agents, which enhance treatment efficacy and patient outcomes. This shift towards personalized medicine solidifies immunotherapy's role in NHL management and fuels market expansion, reflecting a broader trend towards targeted treatment strategies in oncology.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Therapeutic Type & CAGR (2026-2033)

• Market Overview
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Drug class & CAGR (2026-2033)

• Market Overview
• Monoclonal Antibodies
• Chemotherapeutic Agents
• Bruton's Tyrosine Kinase Inhibitors
• Immunomodulators

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Administration Route & CAGR (2026-2033)

• Market Overview
• Intravenous
• Oral
• Subcutaneous

Global Non-Hodgkin Lymphoma Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Diffuse Large B-Cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Burkitt Lymphoma

Global Non-Hodgkin Lymphoma Therapeutics Market Size & CAGR (2026-2033)

• North America (Therapeutic Type, Drug class, Administration Route, Indication)
  • US
  • Canada
• Europe (Therapeutic Type, Drug class, Administration Route, Indication)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapeutic Type, Drug class, Administration Route, Indication)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapeutic Type, Drug class, Administration Route, Indication)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapeutic Type, Drug class, Administration Route, Indication)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seagen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kyowa Kirin Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immuneel Therapeutics Private Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations